On Nov 2, 2021 Cambridge Epigenetix closed a Series D round and raised $88,000,000 from Ahren Innovation Capital, GV, New Science Ventures, Sequoia Capital, Temasek […]
Venture Round – Shoreline Biosciences
On Nov 2, 2021 Shoreline Biosciences closed a Venture – Series Unknown round and raised $140,000,000 from Ally Bridge Group, BeiGene, Boxer Capital, BVF Partners, […]
Series A – Dunad Therapeutics
On Nov 2, 2021 Dunad Therapeutics closed a Series A round and raised $24,000,000 from BioGeneration Ventures, Epidarex Capital, Novartis, featuring lead investors BioGeneration Ventures. […]
Series A – Nitrase Therapeutics
On Nov 2, 2021 Nitrase Therapeutics closed a Series A round and raised $7,000,000 from AbbVie Biotech Ventures, Alexandria Venture Investments, Bristol Myers Squibb, Dementia […]
Series D – Antiva Biosciences
On Nov 2, 2021 Antiva Biosciences closed a Series D round and raised $31,000,000 from Adjuvant Capital, Alexandria Venture Investments, Avestria Ventures, Brace Pharma, Canaan […]
Series B – Biolinq
On Nov 2, 2021 Biolinq closed a Series B round and raised $100,000,000 from Able Partners, Aphelion Capital, Ascensia Diabetes Care, AXA Investment Managers, Cirrus […]
Series D – Cambridge Epigenetix
On Nov 2, 2021 Cambridge Epigenetix closed a Series D round and raised $88,000,000 from Ahren Innovation Capital, GV, New Science Ventures, Sequoia Capital, Temasek […]
Venture Round – Shoreline Biosciences
On Nov 2, 2021 Shoreline Biosciences closed a Venture – Series Unknown round and raised $140,000,000 from Ally Bridge Group, BeiGene, Boxer Capital, BVF Partners, […]
Grant – InterveXion Therapeutics
On Nov 1, 2021 InterveXion Therapeutics closed a Grant round and raised $13,800,000 from National Institutes of Health, featuring lead investors National Institutes of Health. […]
Post-IPO Equity – Valneva
On Nov 1, 2021 Valneva closed a Post-IPO Equity round and raised €88,000,000 from investors, featuring lead investors . About the company: Valneva is located […]
